KSSP supports distribution of generic drugs for SMA patients in Keralam

Kerala Sastra Sahitya Parishad (KSSP), a cultural and scientific organization in the state, has announced its support for the wider distribution of generic medicines that treat spinal muscular atrophy (SMA). President C. Ramakrishnan and General Secretary V. Manoj Kumar said that making the drug available to patients will improve both quality of life and life expectancy. Their statement was made during a recent meeting with health officials and patient groups, highlighting the need for affordable treatment options in Kerala statewide.

Spinal muscular atrophy is a rare genetic disorder that weakens the muscles responsible for breathing, swallowing and movement, often leading to early mortality. Until recently, the only approved therapies were high‑cost branded products that many families could not afford, especially in rural parts of Kerala where health insurance coverage is limited. Generic versions of the drug have been approved by the national regulator, offering a price reduction of up to seventy percent. By championing their distribution, KSSP hopes to bridge the gap between medical advances and the people who need them most.

The immediate effect of the initiative is expected to be a rise in the number of SMA patients receiving timely treatment, which can slow disease progression and extend survival. Health officials in Kerala have pledged to work with pharmacies and hospitals to ensure that the generic medicine reaches both urban clinics and remote health centers. For Indian readers, the move illustrates how regional organizations can influence national health policy, encouraging other states to adopt similar models that prioritize affordable access to life‑saving drugs.